Literature DB >> 12097459

Natural history and distribution of bone and bone marrow infarction in sickle hemoglobinopathies.

Sam K Kim1, John H Miller.   

Abstract

METHODS: Over a period of 11 y, 50 patients (22 males, 28 females; age range, 8 mo to 22 y) presenting with sickle cell-associated bone pain underwent 93 sequential examinations with 99mTc-sulfur colloid bone marrow scanning and 99mTc-diphosphonate bone scanning. Multiple examinations were performed on 21 patients. The number and distribution of total acute, healed, and nonhealed infarcts by location were recorded on a skeletal homunculus.
RESULTS: For this population, the total number of sites of bone and bone marrow infarction was 464. Of these, 175 were classified as acute by clinical and scintigraphic findings. There were a total of 61 nonhealed sites and 162 healed sites.
CONCLUSION: Knowledge of the distribution and natural history of sites of bone and bone marrow infarction is of considerable clinical and diagnostic import in the ongoing evaluation and treatment of sickle hemoglobinopathies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097459

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Bone marrow necrosis in sickle cell anaemia.

Authors:  Panayiotis D Ziakas; Michael Voulgarelis
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

Review 2.  Regenerating new heart with stem cells.

Authors:  Piero Anversa; Jan Kajstura; Marcello Rota; Annarosa Leri
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

3.  Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.

Authors:  Vicky Chaar; Sandrine Laurance; Claudine Lapoumeroulie; Sylvie Cochet; Maria De Grandis; Yves Colin; Jacques Elion; Caroline Le Van Kim; Wassim El Nemer
Journal:  J Biol Chem       Date:  2014-03-10       Impact factor: 5.157

Review 4.  Antibiotics for treating osteomyelitis in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Luis H Agreda-Pérez
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

Review 5.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

6.  Multiple bone and joint diseases in a nigerian sickle cell anaemia: a case report.

Authors:  John A Olaniyi; Adekunle E Alagbe; Toluwalase A Olutoogun; Oluwasogo E Busari
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-05-07       Impact factor: 2.576

7.  Treatment for avascular necrosis of bone in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Luis H Agreda-Pérez
Journal:  Cochrane Database Syst Rev       Date:  2019-12-05

8.  Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion.

Authors:  Shin-Young Park; Alessandro Matte; Yookyung Jung; Jina Ryu; Wilson Babu Anand; Eun-Young Han; Min Liu; Carmine Carbone; Davide Melisi; Takashi Nagasawa; Joseph J Locascio; Charles P Lin; Leslie E Silberstein; Lucia De Franceschi
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

Review 9.  Systemic lupus erythematosus in patients with sickle cell disease.

Authors:  Simone Appenzeller; Andre Fattori; Sarita T Saad; Lilian T L Costallat
Journal:  Clin Rheumatol       Date:  2007-11-14       Impact factor: 3.650

Review 10.  Antibiotics for treating osteomyelitis in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Luis H Agreda-Pérez
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.